ADOCIA SAS (ADOC.PA)
FR0011184241 - Common Stock
ADOC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 69 industry peers in the Biotechnology industry. ADOC has a bad profitability rating. Also its financial health evaluation is rather negative. ADOC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year ADOC has reported negative net income.
In the past year ADOC has reported a negative cash flow from operations.
ADOC had negative earnings in each of the past 5 years.
In the past 5 years ADOC always reported negative operating cash flow.
1.2 Ratios
ADOC's Return On Assets of -87.56% is on the low side compared to the rest of the industry. ADOC is outperformed by 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.56% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-61.02%
ROA(5y)-52.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ADOC (264.82%) is better than 100.00% of its industry peers.
ADOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 264.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADOC has more shares outstanding than it did 1 year ago.
ADOC has more shares outstanding than it did 5 years ago.
ADOC has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.56, we must say that ADOC is in the distress zone and has some risk of bankruptcy.
ADOC has a worse Altman-Z score (-2.56) than 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.56 |
ROIC/WACCN/A
WACC7.31%
2.3 Liquidity
A Current Ratio of 0.92 indicates that ADOC may have some problems paying its short term obligations.
The Current ratio of ADOC (0.92) is worse than 75.00% of its industry peers.
ADOC has a Quick Ratio of 0.92. This is a bad value and indicates that ADOC is not financially healthy enough and could expect problems in meeting its short term obligations.
ADOC has a Quick ratio of 0.89. This is in the lower half of the industry: ADOC underperforms 71.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.92 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
ADOC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.18%, which is quite impressive.
ADOC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -90.86%.
The Revenue for ADOC have been decreasing by -46.13% on average. This is quite bad
EPS 1Y (TTM)35.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.25%
Revenue 1Y (TTM)-90.86%
Revenue growth 3Y36.74%
Revenue growth 5Y-46.13%
Sales Q2Q%-100%
3.2 Future
ADOC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.53% yearly.
ADOC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.43% yearly.
EPS Next Y47.15%
EPS Next 2Y15.82%
EPS Next 3Y0%
EPS Next 5Y0.53%
Revenue Next Year68.06%
Revenue Next 2Y35.4%
Revenue Next 3Y31.04%
Revenue Next 5Y23.43%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ADOC. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 1.75, the valuation of ADOC can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ADOC indicates a rather cheap valuation: ADOC is cheaper than 98.44% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.86, ADOC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.75 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.82%
EPS Next 3Y0%
5. Dividend
5.1 Amount
ADOC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADOCIA SAS
EPA:ADOC (12/30/2024, 5:27:24 PM)
5.9
+0.09 (+1.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.76%
Inst Owner ChangeN/A
Ins Owners9.4%
Ins Owner ChangeN/A
Market Cap91.27M
Analysts82.5
Price Target9.33 (58.14%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.75 | ||
| P/S | 174.52 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.53
EYN/A
EPS(NY)3.37
Fwd EY57.05%
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0.03
BVpS-0.5
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.56% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 264.82% | ||
| FCFM | N/A |
ROA(3y)-61.02%
ROA(5y)-52.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 35.98% | ||
| Cap/Sales | 37.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.92 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | -2.56 |
F-Score5
WACC7.31%
ROIC/WACCN/A
Cap/Depr(3y)30.91%
Cap/Depr(5y)56.87%
Cap/Sales(3y)11.2%
Cap/Sales(5y)30.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.25%
EPS Next Y47.15%
EPS Next 2Y15.82%
EPS Next 3Y0%
EPS Next 5Y0.53%
Revenue 1Y (TTM)-90.86%
Revenue growth 3Y36.74%
Revenue growth 5Y-46.13%
Sales Q2Q%-100%
Revenue Next Year68.06%
Revenue Next 2Y35.4%
Revenue Next 3Y31.04%
Revenue Next 5Y23.43%
EBIT growth 1Y-0.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.26%
EBIT Next 3Y8.66%
EBIT Next 5YN/A
FCF growth 1Y37.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.26%
OCF growth 3YN/A
OCF growth 5YN/A